00:05 Good day, and welcome to the Rapid Micro Biosystems Fourth Quarters 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, this call may be recorded. 0:32 I would like to turn the call over to Mike Beaulieu, Investor Relations. You may begin.

00:37 Good morning, and thank you for joining the Rapid Micro Biosystems fourth quarter and full-year 2021 earnings call. Joining me on the call today are Rob Spignesi, President and Chief Executive Officer; and Sean Wirtjes, Chief Financial Officer. 01:02 Earlier today, we issued a press release announcing our fourth quarter and full-year 2021 financial results. A copy of the release is available on the company's website at rapidmicrobio.com under Investors in the News and Events section. 01:18 Before we begin, I'd like to remind you that many statements made during this call may be considered forward-looking statements within the meaning of Federal Securities Laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements, including but not limited to statements relating to Rapid Micro's financial condition, expectations for business development and growth, customer interest, and adoption of the Growth Direct System, and the potential impact of COVID-19 on Rapid Micro's business. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. 02:05 For a list and description of the risks and uncertainties associated with Rapid Micro's business, please refer to the Risk Factors section of Form S1 filed with the Securities and Exchange Commission on July 12th , 2021. We urge you to consider these factors and you should be aware that these statements should be considered estimates only and are not a guarantee of future performance. 02:27 This conference call contains time sensitive information and is accurate only as of the live broadcast today March 4th, 2022. Rapid Micro disclaims any intention or obligation, except as required by law to update or revise any financial projections or forward-looking statements whether because of new information, future events, or otherwise. 02:48 And with that, I'll now turn the call over to Rob.

02:51 Thank you, Mike. Good morning, everyone, and thank you for joining us to review our fourth quarter and full-year 2021 results. Before getting into the details of our performance, I would like to remind everyone of our mission at Rapid Micro Biosystems. We're focused on revolutionizing microbial quality control or MQC, which is a critical regulated aspect of the global pharmaceutical manufacturing process. 03:16 This process includes a constant testing of raw materials, production environments, personnel in-process materials and final sterility of drug products from microbial contamination, such as bacteria, mold, and other harmful organisms. Our Growth Direct platform fully automates and replaces the traditional manual MQC process, setting the foundation for end-to-end quality control automation to enable the future of advanced pharmaceutical manufacturing. 03:45 We remain very excited about our commercial opportunity. The MQC testing market is large at approximately $10 billion and growing. It is ripe for disruption and under pressure to modernize with little competitive intensity. We count over half of the global top 20 pharmaceutical manufacturers as our customers and our value proposition is resonating strongly. And while we address all pharmaceutical manufacturer modalities, we are especially strong in the fast growing biologics and cell and therapy segments. 04:16 Turning to full-year 2021 results. Total revenue was $23.2 million, which increased 45%, compared to the prior year. This includes commercial revenue of $21.6 million, which increased 54%, compared to 2020. For the full-year 2021, we placed 29 systems and completed the validation of 33 systems. 04:51 On a cumulative basis, we have placed 116 systems as at the end of 2021 is 33% increase, compared to the end of 2020. Additionally, we have validated 84 systems, a 65% increase, compared to last year-end. 05:08 Recurring revenue increased by 100% in 2021, driven by higher consumable…

10:45 Thanks, Rob and good morning everyone. This morning we reported total revenue for the fourth quarter of $5.2 million, which was essentially flat, compared to Q4 last year. Commercial revenue was $4.9 million, down slightly from $5.1 million in the fourth quarter last year, both total and commercial revenue were at the high-end of the range as we pre-announced in early January. 11:07 Within commercial revenue, product revenue was $2.9 million, compared to $4.1 million in the fourth quarter of 2020. This decline was due to lower placements of Growth Direct Systems what was partially offset by strong growth in consumables, which increased over 100%, compared to Q4 2020. 11:24 As we discussed in January the decline in system placements was due to customer site access limitations caused by the rapid onset of omicron and other specific customer timing issues that resulted in the placement of three Growth Direct Systems in the fourth quarter, compared to 10 placements in Q4 2020. 11:40 Systems revenue declined at a rate slightly less than system placements. In contrast, the significant increase in consumables revenue was driven by newly validated systems coming online and increased utilization by some existing customers. Commercial revenue also includes service revenue, which was $2.0 million in the fourth quarter, an increase of 91%, compared to Q4 2020. The increase was largely due to higher revenue from validation services and to a lesser extent recurring service contract revenue. 12:09 During the quarter we completed the validation process on 16 systems, including several that shifted from Q3 into early Q4. On a combined basis the 21 validations we completed in the second half of 2021 met our expectation and sets us up well for continued consumables growth in 2022. 12:29 Non-recurring revenue was $2.6 million in the fourth quarter with…

18:53 [Operator Instructions] Our first question comes from Max Masucci with Cowen. Your line is open.

19:08 Hi, thanks for taking the questions. So, first one is just around the timing of Growth Direct implementation. For biopharma companies that are conducting their drug development and manufacturing in-house, I'm sure it varies for small molecule versus biologic and cell engine therapy customers. But are you seeing these customers implement Growth Direct systems, automated MQC testing capabilities before or after IND filing? Just curious when the ideal time is to introduce a Growth Direct System?

19:48 Yes, Max, this is Rob. Good question, so most of our placements and installations are after commercialization of the product within, again, our broader segment is biologics and cell and gene therapy. Although we do have examples of where we've been purchased and installed and in Phase 3 trials, especially in cell and gene therapy. So that's the composite, I would say, of our current portfolio. That being said, we see opportunity to work upstream in the process and in the Phase -- certainly Phase 3 and possibly in Phase 2 to become part of the manufacturing quality process earlier. And it is one of the key elements of our commercial strategy.

20:43 Great. And then maybe just thinking about demand by customer type. Can you just give us a sense for the demand trends you're seeing for biopharma customers versus CDMOs? And then maybe even if we could split it between biologics companies, cell and gene therapy companies and small molecule. Just be curious to hear, how demand trended for each of those customer types during 2021 and expectations in '22?

21:19 Right. So I would say with the way we look at it and what we've seen is demand was strong, I think you've heard in the prepared remarks with regard to biologics and cell and gene therapies, both from a principal manufacturer standpoint, as well as CDMOs. The majority of our CDMOs is the strong segment for us and majority of those sales are into the biologics and cell and gene therapy categories, but also those companies that are performing principal manufacturing of biologics and cell and gene therapy as we discussed are in the prepared remarks, our value prop is resonating quite strongly. 21:59 The -- our value prop resonate strongly in small molecule and sterile injectables, it’s just less of a current feature of our current portfolio based on the composite I walked you through in the prepared remarks and previously and that's as much to do with our current focus is as any end market demand. And as we expand our commercial team, expansion of our capture of those other segments is certainly in scope. But the demand and value proposition around Biologics generally in cell and gene therapies is remained strong across the -- I would call at the manufacturer type -- principal manufacturer or CDMO.

22:42 Great. Maybe just a final quick one, just -- as the variant impact has cooled off a bit, you're serving a global customer base, but if there's anything you can offer around rebound -- the rebound you've seen in the US versus maybe the EU and rest of world. Omicron has cooled off that would be helpful.

23:10 Yes, yes. So the first part of the quarter looked a lot like Q4, but per Sean's comments although we are seeing green shoots and things getting better in the US in particular, just for example, we had a -- one of our major customers on site last week. It's the first time that's happened in a very long time. Asia, I would say it's probably the most based on our experience, at least the most still and when call it lockdown mode, but in more of a COVID protocol mode. And then Europe is somewhere in between North America and Asia. 23:50 That being said, we are planning a significant customer visit trip in early part of Q2, which we expect to go through with. So we are cautiously optimistic about the restrictions alleviating. It’s still company -- the company and case by case, but we're incrementally optimistic.

24:14 Great, thanks for taking the questions.

24:17 Thank you.

24:20 Our next question comes from Tycho Peterson with J.P. Morgan. Your line is open.

24:26 Hi guys, this is Casey on for Tycho. Thanks for taking my questions.

24:30 Hey, Casey.

24:30 Wanted to get a sense of -- hey. So what's the implied pull-through per system in 2022 guide, both in terms of total instruments and value based and then for the routine use instruments? And then can you give us a sense of how many of the database right now is routine and where do you think that would go by the end of 2022?

24:53 Yes. Casey, it’s Sean. So on the first question focusing on the validated system base, I think what we've got modeled in as a relatively modest increase in that number, that $80,000 number that I mentioned in my remarks. We will expect to see that accelerate over time as we continue to grow that base and more and more of that overall base is already into routine use. 25:17 So, yes think about routine use, we've talked in the past about kind of the lag and the process to get from validation to routine use, it’s different for different customers, it goes typically goes faster for existing customers than new customers. We've got our target three months, we don't have every customer there yet, some take longer than that, we're continuing to work with them to accelerate that process. So we do see significant opportunity and are going at that in a number of different ways. We've talked about some things we're doing to project manage more directly and shrink those time lines down. 25:54 So both that and there are opportunities with customers we're going after to increase utilization of their systems, whether it’d be adding applications, they naturally do it sometimes as they ramp up production, so both of those factors are things that we see as drivers of that metric increasing and accelerating over time.

26:18 Got it. That's helpful. And then on the margin profile of the consumables, usually in our space the consumables have a higher gross margin and then the instrument. So just want to get a better understanding of what goes into the consumables manufacturing process here? And if there's any way to optimize costs there? And then ultimately where do you see the long-term consumable margin shaking out once you guys are at scale?

26:40 Yes, sure. There are lots of opportunities to optimize cost, and we're going after many of them right now. When you think about us, I mean, we talked about this before as well. One of the bigger challenges the consumable margins for us today is just scale. The volume is relatively low. We've made significant and multi-million dollar investments in an automated line and infrastructure to support the growth of us -- ourselves and our customers, adding facilities. We just talked about the Lexington facility that we're adding and going to -- we expect to bring online mid-year. 27:15 So what's going to drive the consumer margins for us, moving from negative to positive and trending up into the 70%-ish range is where we are, which is where we ultimately expect them to get long term, is going to be, us taking cost out of the product. At low volumes, you don't have a lot of leverage with. Suppliers, there are different things we can do as we grow that will help get cost out of product that we've talked about in the past. But volume is a very big provider of leverage in the margins for consumables going forward as well. 27:48 This cost base we've built that we do not expect to grow at anything close to our consumables growth rate and therefore the amount of overhead that gets allocated to an individual consumable over time is going to shrink relatively rapidly, and that will drive a lot of improvement and expansion in consumable margins going forward. So we look out a couple of years from now, we would expect to be in a space where we're moving positive and we'd expect that trajectory to be pretty steep in terms of getting ourselves up to where we ultimately think we can get on a consumable margin overall.

28:20 Got it. Thank you for all the color there. And maybe just curious, how you guys are thinking about client staffing shortages, if there are any, both in terms of near-term impacts to placing and validating instruments? But also on the customer demand side, as this dynamic would likely drop some incremental demand toward an automated, high throughput kind of solution. So, yes, any color there. Thank you.

28:45 Yes, Casey, it's certainly part of our value proposition. Our customers view our system as a way to manage the risk of human labor. So it's definitely a core part of our value prop and resonating, as you may imagine, strongly in the current market. As I touched on previous conversations, it's also not -- it hasn't been a great idea historically to have certainly through COVID, to have a number of people in the lab side by side, looking at petri dishes. So that automation and remote data and data enablement capability we bring as part of the strong value prop, it resonates well with our customers, per my comments in the intro remarks.

29:37 Our next question comes from Dan Arias with Stifel. Your line is open.

29:43 Good morning, guys, thanks for the questions. Sean, when you look at the bucket of routine use systems that drive those consumables pull-through levels that are pretty high 100k, and then I think you said there were some that are over 200k. So what is the average timeline that it took to get to those levels? And then, I guess, what are the characteristics that those customers have in common? And then we can kind of use to conceptualize, who should be getting to what level? And when, I mean, I'm sure overall customer size plays into it, but I'd be curious just to hear when you try to understand who gets to where and when and what the expectation should be there? How we could go about thinking about that?

30:23 Yes, I'll start and I think Rob may have some comments here too. Yes, so in the timeline to get customers from validation to routine use it varies quite a bit historically, we’re -- as I said earlier, trying to narrow that down both shrink it and make it more consistent. And we're making some progress on that, but we've got some work to do. We think there's a lot of opportunity there, which is going to benefit us and get consumables going sooner. 30:48 The three months, I said was the target we have some that are three months, we have some that are to be frank, more than a year, most are in between that. So I don't have an average number for you, but I would think about in the -- somewhere in the middle of that range being where our typical customer would be taken with the time it would be taking a typical customer today to get from validation in routine use. 31:12 In terms of where -- who is that the 200k plus, who is that something less than that. It really has to do with use cases for a specific customer. I think we've said before that cell and gene therapy, the level of testing intensity for EM within that sector is very high. So we would typically expect those kinds of customers. And generally biologics as well, maybe slightly lesser extent to -- in EM particularly to be pulling through high volumes of consumables and generating high volumes of revenue, but it does ultimately come down to use case. And Rob, I'll let you comment a little bit on that as well.

31:50 Yes, sure. I think just to jump off of Sean's comments, I mean that's a spot on, think of it as right now mostly application-driven Dan, so environmental monitoring is our – in a given manufacturing facility at 70%-plus of the volume and our footprint tracks pretty closely to that. So our higher volume and higher yielding systems tend to be the environmental monitoring systems in both cell and gene and biologics. We have some very high examples in both our end segments. 32:26 So our water and bioburden tests are -- tend to be a bit lower volume, but I can also tell you that we've got a focused energy against continuing to maximize system capacity. There is latent capacity in some of our systems around the world and we've got a dedicated team out there that is growing focused on improving application utilization bringing on, for example, if the site has a water system that's being used not at full capacity, partnering with the customer on different parts of the sites or campus to bring more water testing on to maximize the utilization and ultimately could consumable revenue. 33:07 But the highest level, I think of it as we're focused in biologics and cell and gene therapy, it tends to be a very, very high test volume environment for EM and other. And the majority of our sales and forward-looking funnel, it’s important to note is environmental monitoring.

33:23 Yes, the only other thing I'd add to that Dan is just remember that between water bioburden and EM the pricing is quite a bit different roughly 3x or more for water and bioburden, so volume is not the only driver, price is important as you think about how that's working out in the market.

33:40 Right, so some of that latent capacity and some of the systems around the world that becomes an interesting lever over time as well?

33:47 Yes, okay. Okay, helpful. And then just to go back to some of the dynamics in the quarter and some of the things you mentioned, can you just talk to the placement factors that you saw that aren't related to COVID and the extent to which some of them are sort of idiosyncratic or one-time situations. And then looking into the first half of the year, are you getting the sense that there might be any of those that would crop up and that we should kind of factor in when we're thinking about 1Q or 2Q place, it’s aside from what you mentioned?

34:16 Yes, Dan I'll start and Sean will add a couple of comments as well. So the non-COVID and maybe customer related timing issues, and one good example is we had a decent sized multi-system order push to the right due to construction delays. Now the details of that could be related to COVID underlying impact in construction. It's hard to flesh that out at times. But fundamentally, if the size is not prepared, the customer is not ready, it’s extremely difficult to place the system. So that is an example of an idiosyncratic case that was meaningfully sized multi-unit order in the quarter. 34:57 Looking into the first half, do risks of that nature exists at some level? Yes, but the quality and scale of our funnel that we're managing, we're managing around a hedge any risk associated with that, that type of risk will exist, but as we build our sales team out and build our funnel around it, that’s really one of the major countermeasures we have against these types of challenges and having better site access can also help us get ahead of some of these risks as well.

35:30 Yes, just one bit of color on that deal that Rob talked about too, the reason that the construction pushed out or we needed construction at all. I guess, are they needed it, it was because they decided to increase the size of their order. So they needed to put it in a different facility, which ultimately needed construction to fit the systems. So it's a good answer for us, it just – it impact the timing, yes.

35:51 Yes, yes. But it should fall into 2022, so if they want to – if I was thinking initially two in Q4, I could be thinking three in 2020, it’s up 2022 at some point, I mean, the point is like you will capture that order and the sizes larger?

36:06 Yes, sure. That's a good assumption, yes.

36:09 Okay and then just lastly on that funnel that you mentioned just to kind of like calibrate where we are now versus where we were? I think when we were going through the IPO process, the way that it looked -- the funnel looked by customer type was kind of just over two-thirds biopharma and then the rest was CDMO and other? Is that generally the way it looks now? Are you growing the biopharma piece because to your point cell and gene and things like that are picking up and contributing more to the overall demand profile?

36:39 Yes, so I’d say that the biopharma principal manufacturer is still probably in that two-thirds and a big chunk of the rest is CDMO. We tend to look at it as a bit more on end product manufacturing modality. So the combination of biopharma and CDMO is better than 85%-plus and the funnel of those in our funnel their manufacturing specifically biologics and cell and gene therapies.

37:14 So think of it as the vast majority of our funnel is in the biologics and cell and gene therapy category, the biggest single segment is biopharma followed by CDMO.

37:26 Got it. Okay, very good. Thank you, guys.

37:29 Sure.

37:31 Our next question comes from Tejas Savant with Morgan Stanley. Your line is open.

37:37 Hey, guys. Good morning. So one on the 3Q versus 4Q dynamic here, Robert, Sean. Can you just walk us through why you think the site access issues impacted validated systems in 3Q, but the impact shifted predominantly to system placements in 4Q?

38:00 Yes, so, Tejas, if you recall, we picked up the validations pretty quickly in Q4. And what -- and that is related to how customers view critical access and essential activities. So once a system is purchased and is going through the installation process and validation process, that can tend to get -- it's viewed more as an essential type of function and allows our folks to get on site. There's always some noise in that which cause a little bit of delay in between Q3 and Q4 and validations. As you know, we put them back up. 38:45 New sales opportunities a little bit different with regard to our ability to get on-site and get site access, especially with some of our newer opportunities out there. That's just a practical issue associated with how customers run their business and allowed us site access based on the kind of activity that we were performing.

39:06 And, Tejas, just to add to that, I think just more broadly, it's important to remember that at any given point in time, we have a number of validations in process. We measure the metric at the end of a quarter. And in that case, because of the factors that we were seeing, a handful of them slipped a few weeks. If you look back at our historical quarterly validation numbers, they have tended to bounce around because those kinds of things have happened historically. They just were -- have been exacerbated with COVID in some of the access issues that they've created. Although, as Rob said, that it's a bigger issue with the systems -- new system placements than it is with validation. 39:44 So I just -- I want to set an expectation that these things can bounce around between quarters. And we look at it on an annual basis and say, did we meet our goal? Yes, in 2021, we met our goal, and we'll continue to do that. The critical question is what's happening with timing going to impact future consumable sales. I think when we look at the Q3, Q4 example, not in any meaningful way. We don't think so. To the extent that things slowed materially in the future, we'll have -- we'll need to talk about that. But we do see variability and I just want to make sure that we're clear that that's part of the normal business cycle for us.

40:20 Got it. That's helpful. And then just a couple of quick ones on the margins here, you know, I think you've pointed to sort of some of the dynamics in the fourth quarter here on the gross margin line. But are you still targeting gross margin breakeven in '22 on a consolidated basis?

40:39 Yes, we are. At the midpoint of our guidance range, we will be positive on gross margins in the fourth quarter.

40:44 Got it. Great. And then, Sean, on OpEx, I mean, should we be thinking of sort of mid-to-high 40s there with another sort of $8 million or so allocated for the Lexington facility built out?

40:59 OpEx or CapEx, Tejas or you asking --

41:01 Well, both actually, yes.

41:04 Okay. Yes, so on OpEx, I would think about that as being a little bit below what our commercial revenue growth rate will be. So we won’t have it, yes quite the same level be a little bit lower. That's really driven by a couple of things, investments we made in 2021 annualizing. You've asked the other big thing in there is that we're a public company now this will be the first year that we have those costs that we carry with us for an entire year. So the annualization of those drives a little bit higher growth rate in those costs. And as we look forward, we would expect there to be a bigger gap between revenue growth and OpEx growth after this year as we drive toward profitability over time. 41:40 On CapEx, yes the Lexington side is a consideration, there's a couple other relatively significant things in CapEx this year. So the number that you threw out there is probably a relatively fair number to think about CapEx for us this year.

41:55 Got it, helpful. And then it's come up a couple of times before, but I just wanted to talk about like some of the more recent proactive measures you've taken to ensure your customers regarding business continuity. It's a big point of focus, especially given, not just the supply chain pressures, but now also all the geopolitical tensions bringing over here? And in that context, Rob, can you possibly think about sort of plans to accelerate that European facility build out?

42:29 Well, to that point Tejas, during -- I mentioned a visit to see customers early in Q2, the second part of that visit to look at various sites in Europe as well. So it is top of mind for us, just more generally, we continue to hold both upstream and downstream finished goods inventory in both North America and Europe for our customers. We haven't seen any major supply chain disruptions through COVID, up into including current times. We have our principal manufacturing and low and a manual back up there and then of course we're -- as you know we're investing here in Lexington for backup manufacturing as well. And as we discussed, ultimately Europe as well, and but anyway the good timing on the question, because we are focused now on the -- as Lexington is coming to conclusion looking into the European site selection and go forward. Still TBD on the actual project plan around that, but it's very much on the plate for 2022.

43:40 And that'll be probably our number one CapEx investment over the next couple of years after this year.

43:44 Yes, Yes.

43:47 Yes. Got it. That's helpful. And then one final one for me on sterility. Just, Rob, any color on, feedback from customers following the announcement? I think you mentioned the first customer beta starting here in the second quarter? And any color on whether a customer could adopt Growth Direct solely for sterility or often optionality for existing customers to add a new application to the platform?

44:15 Yes, the general feedback that we're getting from customers, especially those of which we're working with on beta is quite excited. So I think there's a need for a rapid sterility application in the market that is married with a system like the Growth Direct, where you have the full walk away automation and all the data integrity benefits. 44:37 And to the second question, we absolutely see a value prop of selling sterility to not only our existing customer base, but new customers as well. It's -- the value prop resonates strongly in our core market of biologics and cell engine therapies. But we also touch a bit about the top of the call here in the Q&A about other segments like sterile injectables and other types of small molecule markets. It also has very high value proposition fit there as well. So we view it as certainly related with regard to the full assay profile that we currently have, but also it can be adopted as a stand-alone assay and system basis. Our goal, obviously, is to acquire the entirety of the workflow in any given customer but there's -- we do envision, sterility maybe the lead dog, if you will, or the lead kind of instrument and assay in new customers.

45:40 Very helpful. Thank you, Rob.

45:43 Sure.

45:45 There are no further questions. I’d like turn the call back over to Rob for any closing remarks.

45:51 Okay. Well, thank you for joining us today. We appreciate your interest in our company. Next week we are attending the Cowen Healthcare Investor Conference and look forward to speaking with many of you there.

46:02 This concludes the program. You may now disconnect. Everyone have a great day.